» Articles » PMID: 10794683

Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration

Overview
Journal J Med Chem
Specialty Chemistry
Date 2000 May 5
PMID 10794683
Citations 206
Authors
Affiliations
Soon will be listed here.
Abstract

A series of very potent derivatives of the 30-amino acid peptide hormone glucagon-like peptide-1 (GLP-1) is described. The compounds were all derivatized with fatty acids in order to protract their action by facilitating binding to serum albumin. GLP-1 had a potency (EC(50)) of 55 pM for the cloned human GLP-1 receptor. Many of the compounds had similar or even higher potencies, despite quite large substituents. All compounds derivatized with fatty acids equal to or longer than 12 carbon atoms were very protracted compared to GLP-1 and thus seem suitable for once daily administration to type 2 diabetic patients. A structure-activity relationship was obtained. GLP-1 could be derivatized with linear fatty acids up to the length of 16 carbon atoms, sometimes longer, almost anywhere in the C-terminal part without considerable loss of potency. Derivatization with two fatty acid substituents led to a considerable loss of potency. A structure-activity relationship on derivatization of specific amino acids generally was obtained. It was found that the longer the fatty acid, the more potency was lost. Simultaneous modification of the N-terminus (in order to obtain better metabolic stability) interfered with fatty acid derivatization and led to loss of potency.

Citing Articles

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP.

Douros J, Flak J, Knerr P Front Endocrinol (Lausanne). 2025; 16:1530985.

PMID: 39963285 PMC: 11830610. DOI: 10.3389/fendo.2025.1530985.


Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity.

Barrea L, Boschetti M, Gangitano E, Guglielmi V, Verde L, Muscogiuri G Curr Obes Rep. 2025; 14(1):1.

PMID: 39753703 DOI: 10.1007/s13679-024-00602-y.


Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review.

Hamed K, Alosaimi M, Ali B, Alghamdi A, Alkhashi T, Alkhaldi S Cureus. 2024; 16(9):e68390.

PMID: 39355484 PMC: 11444311. DOI: 10.7759/cureus.68390.


Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity.

Parums D Med Sci Monit. 2024; 30:e946675.

PMID: 39350608 PMC: 11453121. DOI: 10.12659/MSM.946675.


QnAs with Svetlana Mojsov, Joel Habener, and Lotte Bjerre Knudsen: Winners of the 2024 Lasker~DeBakey Clinical Medical Research Award.

Nair P Proc Natl Acad Sci U S A. 2024; 121(39):e2416868121.

PMID: 39297682 PMC: 11441505. DOI: 10.1073/pnas.2416868121.